Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Farah RahmanTaryn McLaughlinPedro MesquitaJosee MorinDiane PotvinMarilyn De ChantalJudith A AbergPublished in: Journal of clinical and translational science (2022)
Tesamorelin, a synthetic growth hormone-releasing hormone, is indicated for the reduction of visceral adipose tissue (VAT) in people with HIV. Here, we performed a post hoc analysis of participants receiving tesamorelin for 26 weeks in a phase III clinical trial. Efficacy data were compared between individuals with and without dorsocervical fat, stratified by tesamorelin response. Among tesamorelin responders, VAT and waist circumference (WC) decreased in both dorsocervical fat groups and did not statistically differ (VAT P = 0.657, WC P = 0.093). These data demonstrate that tesamorelin is equally effective and should be considered in the treatment of excess VAT regardless of the presence of dorsocervical fat.
Keyphrases
- phase iii
- adipose tissue
- double blind
- clinical trial
- open label
- placebo controlled
- phase ii
- insulin resistance
- antiretroviral therapy
- hiv positive
- human immunodeficiency virus
- hiv infected
- body mass index
- hepatitis c virus
- growth hormone
- high fat diet
- study protocol
- fatty acid
- hiv testing
- hiv aids
- electronic health record
- men who have sex with men
- big data
- physical activity
- combination therapy
- machine learning
- body weight
- artificial intelligence
- data analysis
- skeletal muscle
- south africa
- replacement therapy